Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Drug Abuse Testing Market: By Sample Type, By Technology, By Drug Class and Geography
Drug Abuse Testing Market: By Sample Type, By Technology, By Drug Class and Geography
Drug Abuse Testing (DAT) Market size is valued at US$ 2,507.4 million in 2023 and is expected to reach US$ 3,307.3 million by 2029, at a CAGR of 3.9% from 2024-2030. The workforce drug testing and drug abuse cases mainly drive the drug abuse testing market. The growth of the drug abuse testing (DAT) market is attributed to the increase in usage of alcohol, cannabinoids, cocaine, amphetamines, opiates, and other illicit drugs in various countries across the globe.
The top five drug classes are amphetamines, opiates, alcohol, cocaine, and cannabis, accounting for an 80.8% market share in the global drug abuse testing (DAT) market. The urine sample is highly preferred for initial screening and confirmation. However, the adoption of saliva samples for screening is expected to create lucrative opportunities over the future years due to the manipulation or adulteration of urine samples with synthetic urine by drug abusers. Forensic laboratories prefer hair samples, which may be given for substances abused 90 days back. However, if the person has no hair or short hair, forensic laboratories prefer a nail test. For the majority of urine and saliva samples, immunoassay and onsite testing are highly preferred for initial screening, and positive samples should be confirmed by mass spectrometry.
Study Period
2024-2030Base Year
2023CAGR
3.9%Largest Market
North-AmericaFastest Growing Market
North America
A growing number of drug users across the globe is responsible for the growth of the drug abuse testing market. The increase in the consumption of alcohol and other illicit drugs such as cannabis, cocaine, heroin, and opiates is a major factor in the growth of the global drug abuse testing market over the forecast years. For instance, according to UNODC 2021, approximately 296 Million people had used drugs per year. However, the number of drugs is gradually increasing due to the rapid growth in population, and unemployment is contributing to drug abuse testing growth around the world. Cannabis is a highly used illicit drug, with an estimated approximately 219 Million people per year around the world. In 2021, approximately 36 Million used amphetamines, 22 million used cocaine, and 20 million used ecstasy. In addition, according to UNODC 2021 data, opioids contribute to drug-related harm that includes fatal overdoses. Around 60 million people engaged in non-medical opioid use in 2021, and 31.5 million used mainly opiates (heroin).
The North American drug abuse testing (DAT) market dominates with a 56% market share in terms of the number of tests, followed by Europe and Asia Pacific. In the European region, the UK carries out more than 16 million drug abuse tests every year. In terms of the market value, the USA Drug abuse testing market was valued at USD 1,297.3 million in 2023 and projected to reach USD 1,598.0 million by 2029.
In the United States (USA), amphetamines dominated the drug abuse testing (DAT) market in 2023 with an approximate share of 20%, followed by Opiates with 18%, Alcohol Abuse with 15%, and Cannabinoids with 14% share.
Among all the amphetamines, Methamphetamine was the most frequently identified drug, followed by Amphetamine, N-ethylpentylone, and MDMA. Amphetamine abuse is increasing in the USA due to a surge in the number of Amphetamine prescriptions for certain diseases such as obesity, narcolepsy, or attention deficit hyperactivity disorder (ADHD).
Opiates contributed the second largest share in the USA. Opioid abuse increased till 2016 due to a surge in the adoption of prescription pain relievers such as hydrocodone, oxycodone, oxymorphone, morphine, codeine, fentanyl, and others, which are widely prescribed for moderate to severe pain.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2023 |
US$ 2,507.4 million |
|
Market Size in 2029 |
US$ 3,307.3 million |
|
Market CAGR |
3.9% |
|
By Sample |
|
|
By Technology |
|
|
By Region |
|
Download Free Sample Report
Every year, approximately 222 Million drug abuse tests take place across the globe.
Abbott Laboratories, Danaher Corporation (Beckman Coulter), LabCorp, Dragerwerk AG & Co. KGaA, Quest Diagnostics Inc.
North America is the fastest-growing region for Drug Abuse Testing Market
| 1. Executive Summary |
| 2. Global Drug Abuse Testing Market Introduction |
| 2.1. Global Drug Abuse Testing Market – Taxonomy |
| 2.1.1. Drug Class Type |
| 2.1.2. Sample Type |
| 2.1.3. Technology |
| 2.1.4. Region |
| 3. Global Drug Abuse Testing Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Drug Abuse Testing Market – Competition Landscape |
| 4. Global Drug Abuse Testing Market Snapshot, 2023 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2029 (Revenue, USD Million) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. USA Drug Abuse Testing Market, 2019 - 2023 and Forecast, 2024 - 2029 (Volume and Value) |
| 5.1. Volume Breakdown by Sample Type – 2023 |
| 5.1.1. Urine |
| 5.1.2. Saliva |
| 5.1.3. Hair |
| 5.1.4. Blood |
| 5.1.5. Others |
| 5.2. Volume Breakdown by Technology – 2023 |
| 5.2.1. Immunoassay |
| 5.2.2. Onsite Testing |
| 5.2.3. Mass Spectrometry |
| 5.2.4. Others |
| 5.3. Drug Abuse Testing Market - 2023, by Drug Class, Market Volume (‘000 Tests) and Market Value (‘000 US$) |
| 5.3.1. Amphetamines |
| 5.3.2. Barbiturates |
| 5.3.3. Cannabinoids |
| 5.3.4. Cocaine |
| 5.3.5. Alcohol Abuse |
| 5.3.6. Heroin Substitution Panel |
| 5.3.7. LSD |
| 5.3.8. Designer Drugs |
| 5.3.9. Benzodiazepines |
| 5.3.10. Opiates |
| 5.3.11. Antidepressants |
| 6. Canada Drug Abuse Testing Market, 2019 - 2023 and Forecast, 2024 - 2029 (Volume and Value) |
| 6.1. Volume Breakdown by Sample Type – 2023 |
| 6.1.1. Urine |
| 6.1.2. Saliva |
| 6.1.3. Hair |
| 6.1.4. Blood |
| 6.1.5. Others |
| 6.2. Volume Breakdown by Technology – 2023 |
| 6.2.1. Immunoassay |
| 6.2.2. Onsite Testing |
| 6.2.3. Mass Spectrometry |
| 6.2.4. Others |
| 6.3. Drug Abuse Testing Market - 2023, by Drug Class, Market Volume (‘000 Tests) and Market Value (‘000 US$) |
| 6.3.1. Amphetamines |
| 6.3.2. Barbiturates |
| 6.3.3. Cannabinoids |
| 6.3.4. Cocaine |
| 6.3.5. Alcohol Abuse |
| 6.3.6. Heroin Substitution Panel |
| 6.3.7. LSD |
| 6.3.8. Designer Drugs |
| 6.3.9. Benzodiazepines |
| 6.3.10. Opiates |
| 6.3.11. Antidepressants |
| 7. Germany Drug Abuse Testing Market, 2019 - 2023 and Forecast, 2024 - 2029 (Volume and Value) |
| 7.1. Volume Breakdown by Sample Type – 2023 |
| 7.1.1. Urine |
| 7.1.2. Saliva |
| 7.1.3. Hair |
| 7.1.4. Blood |
| 7.1.5. Others |
| 7.2. Volume Breakdown by Technology – 2023 |
| 7.2.1. Immunoassay |
| 7.2.2. Onsite Testing |
| 7.2.3. Mass Spectrometry |
| 7.2.4. Others |
| 7.3. Drug Abuse Testing Market - 2023, by Drug Class, Market Volume (‘000 Tests) and Market Value (‘000 US$) |
| 7.3.1. Amphetamines |
| 7.3.2. Barbiturates |
| 7.3.3. Cannabinoids |
| 7.3.4. Cocaine |
| 7.3.5. Alcohol Abuse |
| 7.3.6. Heroin Substitution Panel |
| 7.3.7. LSD |
| 7.3.8. Designer Drugs |
| 7.3.9. Benzodiazepines |
| 7.3.10. Opiates |
| 7.3.11. Antidepressants |
| 8. France Drug Abuse Testing Market, 2019 - 2023 and Forecast, 2024 - 2029 (Volume and Value) |
| 8.1. Volume Breakdown by Sample Type – 2023 |
| 8.1.1. Urine |
| 8.1.2. Saliva |
| 8.1.3. Hair |
| 8.1.4. Blood |
| 8.1.5. Others |
| 8.2. Volume Breakdown by Technology – 2023 |
| 8.2.1. Immunoassay |
| 8.2.2. Onsite Testing |
| 8.2.3. Mass Spectrometry |
| 8.2.4. Others |
| 8.3. Drug Abuse Testing Market - 2023, by Drug Class, Market Volume (‘000 Tests) and Market Value (‘000 US$) |
| 8.3.1. Amphetamines |
| 8.3.2. Barbiturates |
| 8.3.3. Cannabinoids |
| 8.3.4. Cocaine |
| 8.3.5. Alcohol Abuse |
| 8.3.6. Heroin Substitution Panel |
| 8.3.7. LSD |
| 8.3.8. Designer Drugs |
| 8.3.9. Benzodiazepines |
| 8.3.10. Opiates |
| 8.3.11. Antidepressants |
| 9. UK Drug Abuse Testing Market, 2019 - 2023 and Forecast, 2024 - 2029 (Volume and Value) |
| 9.1. Volume Breakdown by Sample Type – 2023 |
| 9.1.1. Urine |
| 9.1.2. Saliva |
| 9.1.3. Hair |
| 9.1.4. Blood |
| 9.1.5. Others |
| 9.2. Volume Breakdown by Technology – 2023 |
| 9.2.1. Immunoassay |
| 9.2.2. Onsite Testing |
| 9.2.3. Mass Spectrometry |
| 9.2.4. Others |
| 9.3. Drug Abuse Testing Market - 2023, by Drug Class, Market Volume (‘000 Tests) and Market Value (‘000 US$) |
| 9.3.1. Amphetamines |
| 9.3.2. Barbiturates |
| 9.3.3. Cannabinoids |
| 9.3.4. Cocaine |
| 9.3.5. Alcohol Abuse |
| 9.3.6. Heroin Substitution Panel |
| 9.3.7. LSD |
| 9.3.8. Designer Drugs |
| 9.3.9. Benzodiazepines |
| 9.3.10. Opiates |
| 9.3.11. Antidepressants |
| 9.3.12. Methaqualone |
| 10. Italy Drug Abuse Testing Market, 2019 - 2023 and Forecast, 2024 - 2029 (Volume and Value) |
| 10.1. Volume Breakdown by Sample Type – 2023 |
| 10.1.1. Urine |
| 10.1.2. Saliva |
| 10.1.3. Hair |
| 10.1.4. Blood |
| 10.1.5. Others |
| 10.2. Volume Breakdown by Technology – 2023 |
| 10.2.1. Immunoassay |
| 10.2.2. Onsite Testing |
| 10.2.3. Mass Spectrometry |
| 10.2.4. Others |
| 10.3. Drug Abuse Testing Market - 2023, by Drug Class, Market Volume (‘000 Tests) and Market Value (‘000 US$) |
| 10.3.1. Amphetamines |
| 10.3.2. Cannabinoids |
| 10.3.3. Cocaine |
| 10.3.4. Alcohol Abuse |
| 10.3.5. Heroin Substitution Panel |
| 10.3.6. Benzodiazepines |
| 10.3.7. Opiates |
| 10.3.8. Antidepressants |
| 11. Spain Drug Abuse Testing Market, 2019 - 2023 and Forecast, 2024 - 2029 (Volume and Value) |
| 11.1. Volume Breakdown by Sample Type – 2023 |
| 11.1.1. Urine |
| 11.1.2. Saliva |
| 11.1.3. Hair |
| 11.1.4. Blood |
| 11.1.5. Others |
| 11.2. Volume Breakdown by Technology – 2023 |
| 11.2.1. Immunoassay |
| 11.2.2. Onsite Testing |
| 11.2.3. Mass Spectrometry |
| 11.2.4. Others |
| 11.3. Drug Abuse Testing Market - 2023, by Drug Class, Market Volume (‘000 Tests) and Market Value (‘000 US$) |
| 11.3.1. Amphetamines |
| 11.3.2. Barbiturates |
| 11.3.3. Cannabinoids |
| 11.3.4. Cocaine |
| 11.3.5. Alcohol Abuse |
| 11.3.6. Heroin Substitution Panel |
| 11.3.7. LSD |
| 11.3.8. Designer Drugs |
| 11.3.9. Benzodiazepines |
| 11.3.10. Opiates |
| 11.3.11. Antidepressants |
| 12. Switzerland Drug Abuse Testing Market, 2019 - 2023 and Forecast, 2024 - 2029 (Volume and Value) |
| 12.1. Volume Breakdown by Sample Type – 2023 |
| 12.1.1. Urine |
| 12.1.2. Saliva |
| 12.1.3. Hair |
| 12.1.4. Blood |
| 12.1.5. Others |
| 12.2. Volume Breakdown by Technology – 2023 |
| 12.2.1. Immunoassay |
| 12.2.2. Onsite Testing |
| 12.2.3. Mass Spectrometry |
| 12.2.4. Others |
| 12.3. Drug Abuse Testing Market - 2023, by Drug Class, Market Volume (‘000 Tests) and Market Value (‘000 US$) |
| 12.3.1. Amphetamines |
| 12.3.2. Barbiturates |
| 12.3.3. Cannabinoids |
| 12.3.4. Cocaine |
| 12.3.5. Alcohol Abuse |
| 12.3.6. Heroin Substitution Panel |
| 12.3.7. LSD |
| 12.3.8. Designer Drugs |
| 12.3.9. Benzodiazepines |
| 12.3.10. Opiates |
| 12.3.11. Antidepressants |
| 13. Austria Drug Abuse Testing Market, 2019 - 2023 and Forecast, 2024 - 2029 (Volume and Value) |
| 13.1. Volume Breakdown by Sample Type – 2023 |
| 13.1.1. Urine |
| 13.1.2. Saliva |
| 13.1.3. Hair |
| 13.1.4. Blood |
| 13.1.5. Others |
| 13.2. Volume Breakdown by Technology – 2023 |
| 13.2.1. Immunoassay |
| 13.2.2. Onsite Testing |
| 13.2.3. Mass Spectrometry |
| 13.2.4. Others |
| 13.3. Drug Abuse Testing Market - 2023, by Drug Class, Market Volume (‘000 Tests) and Market Value (‘000 US$) |
| 13.3.1. Amphetamines |
| 13.3.2. Barbiturates |
| 13.3.3. Cannabinoids |
| 13.3.4. Cocaine |
| 13.3.5. Alcohol Abuse |
| 13.3.6. Heroin Substitution Panel |
| 13.3.7. LSD |
| 13.3.8. Designer Drugs |
| 13.3.9. Benzodiazepines |
| 13.3.10. Opiates |
| 13.3.11. Antidepressants |
| 14. China Drug Abuse Testing Market, 2019 - 2023 and Forecast, 2024 - 2029 (Volume and Value) |
| 14.1. Volume Breakdown by Sample Type – 2023 |
| 14.1.1. Urine |
| 14.1.2. Saliva |
| 14.1.3. Hair |
| 14.1.4. Blood |
| 14.1.5. Others |
| 14.2. Volume Breakdown by Technology – 2023 |
| 14.2.1. Immunoassay |
| 14.2.2. Onsite Testing |
| 14.2.3. Mass Spectrometry |
| 14.2.4. Others |
| 14.3. Drug Abuse Testing Market - 2023, by Drug Class, Market Volume (‘000 Tests) and Market Value (‘000 US$) |
| 14.3.1. Amphetamines |
| 14.3.2. Barbiturates |
| 14.3.3. Cannabinoids |
| 14.3.4. Cocaine |
| 14.3.5. Alcohol Abuse |
| 14.3.6. Heroin Substitution Panel |
| 14.3.7. LSD |
| 14.3.8. Designer Drugs |
| 14.3.9. Benzodiazepines |
| 14.3.10. Opiates |
| 14.3.11. Antidepressants |
| 15. Korea Drug Abuse Testing Market, 2019 - 2023 and Forecast, 2024 - 2029 (Volume and Value) |
| 15.1. Volume Breakdown by Sample Type – 2023 |
| 15.1.1. Urine |
| 15.1.2. Saliva |
| 15.1.3. Hair |
| 15.1.4. Blood |
| 15.1.5. Others |
| 15.2. Volume Breakdown by Technology – 2023 |
| 15.2.1. Immunoassay |
| 15.2.2. Onsite Testing |
| 15.2.3. Mass Spectrometry |
| 15.2.4. Others |
| 15.3. Drug Abuse Testing Market - 2023, by Drug Class, Market Volume (‘000 Tests) and Market Value (‘000 US$) |
| 15.3.1. Amphetamines |
| 15.3.2. Barbiturates |
| 15.3.3. Cannabinoids |
| 15.3.4. Cocaine |
| 15.3.5. Alcohol Abuse |
| 15.3.6. Heroin Substitution Panel |
| 15.3.7. LSD |
| 15.3.8. Designer Drugs |
| 15.3.9. Benzodiazepines |
| 15.3.10. Opiates |
| 15.3.11. Antidepressants |
| 16. Australia Drug Abuse Testing Market, 2019 - 2023 and Forecast, 2024 - 2029 (Volume and Value) |
| 16.1. Volume Breakdown by Sample Type – 2023 |
| 16.1.1. Urine |
| 16.1.2. Saliva |
| 16.1.3. Hair |
| 16.1.4. Blood |
| 16.1.5. Others |
| 16.2. Volume Breakdown by Technology – 2023 |
| 16.2.1. Immunoassay |
| 16.2.2. Onsite Testing |
| 16.2.3. Mass Spectrometry |
| 16.2.4. Others |
| 16.3. Drug Abuse Testing Market - 2023, by Drug Class, Market Volume (‘000 Tests) and Market Value (‘000 US$) |
| 16.3.1. Amphetamines |
| 16.3.2. Cannabinoids |
| 16.3.3. Cocaine |
| 16.3.4. Alcohol Abuse |
| 16.3.5. Heroin Substitution Panel |
| 16.3.6. Designer Drugs |
| 16.3.7. Benzodiazepines |
| 16.3.8. Opiates |
| 16.3.9. Antidepressants |
| 17. Brazil Drug Abuse Testing Market, 2019 - 2023 and Forecast, 2024 - 2029 (Volume and Value) |
| 17.1. Volume Breakdown by Sample Type – 2023 |
| 17.1.1. Urine |
| 17.1.2. Saliva |
| 17.1.3. Hair |
| 17.1.4. Blood |
| 17.1.5. Others |
| 17.2. Volume Breakdown by Technology – 2023 |
| 17.2.1. Immunoassay |
| 17.2.2. Onsite Testing |
| 17.2.3. Mass Spectrometry |
| 17.2.4. Others |
| 17.3. Drug Abuse Testing Market - 2023, by Drug Class, Market Volume (‘000 Tests) and Market Value (‘000 US$) |
| 17.3.1. Amphetamines |
| 17.3.2. Barbiturates |
| 17.3.3. Cannabinoids |
| 17.3.4. Cocaine |
| 17.3.5. Alcohol Abuse |
| 17.3.6. Heroin Substitution Panel |
| 17.3.7. Designer Drugs |
| 17.3.8. Benzodiazepines |
| 17.3.9. Opiates |
| 17.3.10. Antidepressants |
| 18. Central America Drug Abuse Testing Market, 2019 - 2023 and Forecast, 2024 - 2029 (Volume and Value) |
| 18.1. Volume Breakdown by Sample Type – 2023 |
| 18.1.1. Urine |
| 18.1.2. Saliva |
| 18.1.3. Hair |
| 18.1.4. Blood |
| 18.1.5. Others |
| 18.2. Volume Breakdown by Technology – 2023 |
| 18.2.1. Immunoassay |
| 18.2.2. Onsite Testing |
| 18.2.3. Mass Spectrometry |
| 18.2.4. Others |
| 18.3. Drug Abuse Testing Market - 2023, by Drug Class, Market Volume (‘000 Tests) and Market Value (‘000 US$) |
| 18.3.1. Amphetamines |
| 18.3.2. Barbiturates |
| 18.3.3. Cannabinoids |
| 18.3.4. Cocaine |
| 18.3.5. Alcohol Abuse |
| 18.3.6. Heroin Substitution Panel |
| 18.3.7. LSD |
| 18.3.8. Designer Drugs |
| 18.3.9. Benzodiazepines |
| 18.3.10. Opiates |
| 18.3.11. Antidepressants |
| 19. Competition Landscape |
| 19.1. Accuquik Test Kits |
| 19.2. Advin Biotech |
| 19.3. Alere, Inc. (Abbott) |
| 19.4. Alfa Scientific Designs, Inc. |
| 19.5. Andatech |
| 19.6. ARK Diagnostics |
| 19.7. Biopanda Reagents |
| 19.8. Beckman Coulter |
| 19.9. BTNX, Inc. |
| 19.10. Corolina Liquid Chemistries |
| 19.11. Chromsystems, Inc. |
| 19.12. Co-Innovation Biotech Co., Ltd. |
| 19.13. Confirm Biosciences |
| 19.14. Diagnostic Automation/Cortez Diagnostics Inc. |
| 19.15. Diasystems Scandinevia AB |
| 19.16. Germaine Laboratories, Inc. |
| 19.17. Innovative Testing Solution |
| 19.18. Immunostics, Inc. |
| 19.19. Medacx Ltd. |
| 19.20. Meridian Healthcare srl |
| 19.21. Mossman Associates |
| 19.22. Neogen Corporation |
| 19.23. Orasure Technologies, Inc. |
| 19.24. Pharmatech, Inc. |
| 19.25. Premier Biotech |
| 19.26. Prospectol |
| 19.27. Sekisui Diagnostics |
| 19.28. Siemens Healthineers |
| 19.29. Thermo Fisher Scientific, Inc. |
| 20. Research Methodology |
| 21. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.